The Chondrosarcoma market, estimated to be valued at USD 1,028.5 Million in 2025, is expected to grow at a robust CAGR of 7.0%, reaching USD 1,651.6 Million by 2032.

Market expansion is driven by the rising incidence of rare bone cancers, increasing adoption of advanced imaging techniques for early detection, and growing availability of targeted therapies and surgical interventions. Advancements in molecular diagnostics and precision oncology are improving treatment outcomes, while ongoing clinical trials for novel immunotherapies and chemotherapy combinations are expected to further enhance the therapeutic landscape. Additionally, increasing research funding, collaborations among oncology centers, and patient access to specialized cancer care are projected to support the market growth over the forecast period.

Market Takeaways

• By Treatment Option, the Surgery (Curative Treatment) segment is projected to dominate the Chondrosarcoma market with a 60.5% share in 2025. This dominance is driven by the fact that surgical resection remains the primary and most effective curative approach, as conventional chondrosarcomas often exhibit resistance to chemotherapy and radiotherapy.
• By Drug Type, the Conventional Treatments segment is expected to account for the largest share of 70.2% in 2025, owing to the continued reliance on established surgical and supportive care approaches, given the limited efficacy of existing systemic therapies. However, the Emerging Drugs segment, including Ivosidenib and INBRX-109, is anticipated to gain traction due to advancements in targeted therapy and precision oncology.
• Regionally, North America is forecast to dominate the Chondrosarcoma market in 2025, supported by the presence of specialized oncology centers, high adoption of advanced imaging and surgical techniques, strong clinical research activity, and favorable access to emerging therapies through clinical trial networks.

Chondrosarcoma Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/chondrosarcoma-market

Market Dynamics

The Chondrosarcoma market is experiencing steady growth, primarily driven by the rising incidence of rare bone tumors and increasing adoption of advanced diagnostic imaging modalities for early detection. Surgical resection remains the cornerstone of curative treatment, as conventional chondrosarcomas exhibit inherent resistance to chemotherapy and radiotherapy. This clinical reality sustains strong demand for surgical expertise and integrated multidisciplinary care in oncology centers worldwide.

In parallel, advancements in molecular diagnostics and precision oncology are reshaping the therapeutic landscape. The identification of isocitrate dehydrogenase (IDH) mutations has paved the way for targeted therapies, including IDH inhibitors such as Ivosidenib, while DR5 agonists like INBRX-109 are showing promise in clinical trials for refractory or metastatic chondrosarcoma. Ongoing research into immunotherapy combinations and molecularly guided treatment approaches is expected to enhance long-term patient outcomes.

In August 2022, Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the European Commission ("EC"), based on a positive opinion issued by the European Medicines Agency ("EMA"), had granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.

Moreover, supportive government initiatives, rare cancer research funding, and growing collaborations between academic institutions and pharmaceutical companies are propelling innovation in the field. In emerging markets across Asia Pacific and Latin America, rising healthcare expenditure, improved awareness, and the gradual adoption of molecular diagnostics are expected to further drive the market growth during the forecast period.

Market Trends

• Advancements in Targeted and Precision Therapies Driving Innovation

The chondrosarcoma treatment landscape is witnessing a major shift toward precision oncology, focusing on molecularly guided therapies to address the limitations of conventional chemotherapy and radiotherapy. The discovery of isocitrate dehydrogenase (IDH) mutations in conventional chondrosarcoma has spurred the development of targeted therapies such as Ivosidenib (IDH1 inhibitor), while DR5 agonists like INBRX‑109 are demonstrating promising efficacy in refractory cases.

In November 2022, Inhibrx presented updated Phase I data showing 87.9% disease control with INBRX‑109, and in 2024, long-term follow-up of Ivosidenib trials confirmed sustained disease stabilization in multiple patients for over 6 years. This trend reflects the growing role of biomarker-driven treatments in improving patient outcomes.

• Increased Adoption of Molecular Diagnostics and Imaging Technologies

The chondrosarcoma market is witnessing a growing reliance on advanced molecular diagnostics and high-resolution imaging to improve early detection, precise tumor characterization, and patient stratification for targeted therapies. Conventional diagnostic approaches often struggle to differentiate between low- and high-grade chondrosarcomas or detect subtle disease progression, making molecular and imaging innovations crucial for optimal treatment planning.

Modern imaging modalities such as high-resolution MRI and positron emission tomography-computed tomography (PET‑CT) are increasingly used in combination to identify tumor activity, local invasion, and distant metastasis more accurately. MRI provides superior soft tissue contrast, allowing the detailed assessment of cartilage tumors and adjacent structures, while PET‑CT aids in detecting aggressive tumor behavior and guiding surgical margins. These techniques are particularly valuable for monitoring tumor recurrence post-surgery, where conventional radiographs may be insufficient.

On the molecular front, next-generation sequencing (NGS) and liquid biopsy technologies are transforming the diagnostic and prognostic landscape. NGS enables the identification of actionable genetic mutations, such as IDH1/IDH2 mutations, which are present in a significant proportion of conventional chondrosarcomas. Detecting these mutations not only assists in confirming the diagnosis but also stratifies patients for targeted therapies like Ivosidenib. Liquid biopsies, leveraging circulating tumor DNA (ctDNA), are emerging as a non-invasive monitoring tool, allowing clinicians to track minimal residual disease and predict relapse earlier than imaging alone.

Several oncology centers in North America and Europe have integrated molecular profiling panels into the clinical workflow for sarcoma patients. This has enabled earlier enrollment into precision oncology trials, such as those evaluating INBRX‑109 and Ivosidenib, and has shortened the time to initiate appropriate therapy. Moreover, collaborations between diagnostic labs, biotech companies, and academic cancer centers are accelerating the availability of comprehensive sarcoma panels that combine genomic, transcriptomic, and proteomic insights, which will further refine patient management and market adoption.

Market Opportunities

• Orphan Drug and Rare Cancer Development Incentives

Chondrosarcoma is a rare malignant bone tumor, making it eligible for orphan disease status in both the U.S. and the European Union. This designation creates strategic opportunities for pharmaceutical and biotech companies by offering a range of regulatory, financial, and commercial benefits designed to stimulate drug development for small patient populations.

One of the key advantages of orphan drug status is the reduction in time-to-market through pathways such as Fast Track and Priority Review, which streamline regulatory processes and accelerate therapy availability. Developers also benefit from fee waivers and clinical trial tax credits, significantly lowering the cost of research and development in rare cancer indications. Furthermore, approved orphan drugs enjoy market exclusivity—seven years in the U.S. and ten years in the EU—which provides a strong commercial incentive for investment despite the limited patient base.

Beyond financial benefits, orphan drug designation provides enhanced scientific and regulatory guidance, helping companies navigate the challenges of designing trials for small populations. This is particularly important in chondrosarcoma, where traditional chemotherapy and radiotherapy show limited efficacy. The orphan pathway therefore, encourages the development of precision therapies and biologics, enabling biopharma companies to focus on molecularly targeted agents and immunotherapeutic approaches that address the unmet clinical needs of patients with this rare and aggressive cancer.

• Untapped Potential in Emerging Markets

Rising healthcare expenditure and expanding oncology infrastructure in Asia Pacific, Latin America, and the Middle East present opportunities for market penetration. Establishing molecular diagnostic services, specialized sarcoma treatment centers, and access to clinical trials in these regions can drive significant future growth.

In January 2025, ASCO Publications released a case report titled “Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America. The report highlighted that Argentina’s National Cancer Control Plan had piloted telemedicine initiatives for rare cancers, aimed at expanding specialized sarcoma diagnostic capacity, enabling remote pathology reviews, and facilitating multidisciplinary care through a hub‑and‑spoke model.

Analyst View

• The Chondrosarcoma market is undergoing a pivotal transformation driven by the integration of molecular diagnostics, precision oncology, and targeted therapeutics. The market is increasingly shifting toward biomarker-driven treatment strategies, addressing the historical limitations of conventional chemotherapy and radiotherapy in this rare cancer segment.
• Surgical resection remains the primary curative treatment, maintaining its dominance in the market; however, the emergence of novel therapies—notably Ivosidenib (IDH1 inhibitor) and INBRX‑109 (DR5 agonist)—is reshaping the therapeutic landscape. These agents leverage orphan drug designations, Fast Track approvals, and clinical trial incentives, facilitating accelerated development and potential long-term market exclusivity.
• Diagnostic innovation plays a central role in market growth, with next‑generation sequencing (NGS), liquid biopsies, and advanced imaging modalities (MRI and PET‑CT) enabling early detection, tumor characterization, and precise patient stratification. Between 2022 and 2025, multiple oncology centers in North America and Europe have integrated molecular profiling panels, improving trial enrollment efficiency and enhancing outcomes in high‑risk and metastatic cases.
• North America is expected to maintain its market leadership, supported by strong research infrastructure, clinical trial networks, and access to emerging therapies, while Asia Pacific and Latin America represent high‑potential markets due to rising healthcare expenditure, expanding oncology infrastructure, and adoption of telemedicine initiatives for rare cancers. Notably, Argentina’s National Cancer Control Plan and regional initiatives like LACOG’s sarcoma telemedicine pilots are creating pathways for improved diagnosis and treatment access in underserved regions.
• Looking forward, the market is expected to focus on precision therapies, immunotherapy combinations, and molecularly guided treatment protocols. Companies that invest in orphan drug development, regional clinical expansion, and integrated diagnostic‑therapeutic ecosystems will be best positioned to capture the next wave of growth in the global Chondrosarcoma market.

Key Developments

In June 2025, Bristol Myers Squibb-supported cohort evaluating sunitinib plus nivolumab in Extraskeletal Myxoid Chondrosarcoma, demonstrating promising efficacy in this ultra-rare subtype.

Competitive Landscape

• Inhibrx
• Servier
• Pfizer
• Eli Lilly and Company
• Novartis
• Bristol Myers Squibb
• Roche

Chondrosarcoma Market Segmentation

• By Treatment Option
• Surgery (Curative Treatment)
• Chemotherapy (Limited Efficacy)
• Radiotherapy (Resistance in Conventional Types)
• Targeted Therapies (IDH Inhibitors, DR5 Agonists)
• By Drug Type
• Conventional Treatments
• Emerging Drugs (Ivosidenib, INBRX-109)

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • France
  • Russia
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • Japan
  • China
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa